| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,180,493 ) |
| | 2024 | 2024 | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY | SUZANNE TASSIERSTRAAT 1 | GENT | | | | BEL | R01AG079234 | Heterotypic amyloid interactions as modulators of selective cellular vulnerability | 000 | 3 | NIH | 5/31/2024 | $510,259 |
| | 2024 | 2024 | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY | SUZANNE TASSIERSTRAAT 1 | GENT | | | | BEL | R01AG084672 | The TMEM106B-GRN-TDP43 triad: leveraging human samples and humanized models to unravel FTLD-TDP disease mechanisms | 000 | 1 | NIH | 9/9/2024 | $538,380 |
| | 2024 | 2024 | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY | RIJVISSCHESTRAAT 120 | GENT | | | | BEL | R21CA277279 | Mapping ductal carcinoma in situ in space and time to reveal biomarkers that can predict invasive risk | 000 | 1 | NIH | 4/5/2024 | $131,854 |
|
| Issue Date FY: 2023 ( Subtotal = $521,707 ) |
| | 2023 | 2023 | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY | RIJVISSCHESTRAAT 120 | GENT | | | | BEL | R01AG079234 | Heterotypic amyloid interactions as modulators of selective cellular vulnerability | 001 | 2 | NIH | 6/21/2023 | $521,707 |
| | 2023 | 2022 | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY | RIJVISSCHESTRAAT 120 | GENT | | | | BEL | R01AG079234 | Heterotypic amyloid interactions as modulators of selective cellular vulnerability | 000 | 1 | NIH | 10/19/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $523,651 ) |
| | 2022 | 2022 | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY | RIJVISSCHESTRAAT 120 | GENT | GENT | | | BEL | R01AG079234 | Heterotypic amyloid interactions as modulators of selective cellular vulnerability | 000 | 1 | NIH | 9/21/2022 | $523,651 |
| | 2022 | 2020 | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY | RIJVISSCHESTRAAT 120 | GENT | | | | BEL | R01CA201537 | Inter-regulatory function of immune-modulation and angiogenesis in cancer | 000 | 5 | NIH | 1/31/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $21,735 ) |
| | 2021 | 2020 | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY | RIJVISSCHESTRAAT 120 | GENT | GENT | | | BEL | R01CA201537 | Inter-regulatory function of immune-modulation and angiogenesis in cancer | 001 | 5 | NIH | 12/11/2020 | $21,735 |
|
| Issue Date FY: 2020 ( Subtotal = $247,046 ) |
| | 2020 | 2020 | VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY VZW | RIJVISSCHESTRAAT 120 | GENT | GENT | 9052 | | BEL | R01CA201537 | Inter-regulatory function of immune-modulation and angiogenesis in cancer | 001 | 5 | NIH | 7/31/2020 | $247,046 |
|
|
